PRESS RELEASE THOUSAND OAKS.

We believe that talimogene laherparepvec offers potential to help patients in a number of cancer types predicated on its mechanism of action to market tumor antigen launch and presentation, important actions in activating a systemic immune response, saidSean E. Harper, M.D., executive vice president of Research and Advancement at Amgen. This further builds our alliance network in oncology and we anticipate collaborating withRocheon this study as part of our increasing attempts in immuno-oncology. Atezolizumab is certainly our most advanced cancer immunotherapy with 10 ongoing Phase 3 pivotal trials across lung, bladder, kidney and breast cancers, saidSandra Horning, M.D., chief medical officer and mind of Global Product Development atRoche.Reporting its work in the journal Nature Materials, a research group headed by Yi-Yan Yang, Ph.D., describes its development of a novel core-shell nanoparticle manufactured from a biodegradable polymer. Both water-soluble is included by This polymer, or hydrophilic, and fat-soluble, or hydrophobic, elements, which in turn causes the polymer to self-assemble into a core-shell structure when dissolved in water. The core includes a hydrophobic, cholesterol-rich region, providing a suitable environment for entrapping huge quantities of water-insoluble medicines such as paclitaxel. At the same time, the hydrophilic nanoparticle shell creates a stable environment for binding nucleic acid therapeutics, including DNA and siRNA. To determine if these nanoparticles could effectively deliver their payload to tumor cells, the investigators used a construct made up of a gene that expresses green fluorescent protein as well as paclitaxel and added this nanoparticle to breast malignancy cells growing in lifestyle.